Status:
UNKNOWN
The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults.
Lead Sponsor:
Shanghai Cell Therapy Group Co.,Ltd
Collaborating Sponsors:
Shanghai Mengchao Cancer Hospital
Conditions:
NAD+/NADH in Peripheral Blood Monitoring
Eligibility:
All Genders
18-85 years
Brief Summary
This study investigates the concentration levels of NAD+/NADH in peripheral blood samples and immune cells of healthy adults of different age groups under daily physiological and lifestyle conditions,...
Detailed Description
In this study, 60 subjects will be enrolled in three groups according to the age range of 20-40, 41-60 and 61-80. Each group has 20 subjects, and the sex ratio of each group is 1:1. After each partici...
Eligibility Criteria
Inclusion
- 1\. Male/females of 18 to 85 years of age.
- 2\. Able to provide written Informed Consent.
- 3\. Body Mass Index ranging from 18 to 25 kg/m2(bounds included), with a stable weight over the last 2 months (±2.5 kg).
- 4\. Able to follow verbal and written study directions.
- 5\. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
- Able to maintain consistent diet and lifestyle habits according to the study
Exclusion
- 1\. Male/females of 18 to 85 years of age.
- 2\. Able to provide written Informed Consent.
- 3\. Body Mass Index ranging from 18 to 25 kg/m2(bounds included), with a stable weight over the last 2 months (±2.5 kg).
- 4\. Able to follow verbal and written study directions.
- 5\. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
- 6\. Able to maintain consistent diet and lifestyle habits according to the study.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05997628
Start Date
August 1 2023
End Date
August 1 2024
Last Update
August 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Mengchao Cancer Hospital
Shanghai, Shanghai Municipality, China